<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786889</url>
  </required_header>
  <id_info>
    <org_study_id>ANGI HE-1110</org_study_id>
    <secondary_id>2012-A00739-34 (IDRCB Number)</secondary_id>
    <nct_id>NCT01786889</nct_id>
  </id_info>
  <brief_title>Identification, Molecular Epidemiology Angiosarcoma of the Liver France</brief_title>
  <acronym>ANGIHE</acronym>
  <official_title>Identification, Molecular Epidemiology Angiosarcoma of the Liver France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Veille Sanitaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the feasibility of identifying incident cases of
      angiosarcoma of the liver from the network NetSarc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves a questionnaire and a one-hour telephone interview.

      Consultation:

        -  Study proposal

        -  Information and collection of the patient's and/or parent's written consents

        -  Blood collection (10ml) and urine collection of the patient and parents if applicable

        -  Delivery of a specific questionnaire and a stamped envelope (with the address of the
           coordinator's center). If it's about a child patient or an adolescent under 18 years, 3
           questionnaires will be given (1 for each parent and 1 for the child).

      At home: Filling the questionnaire by the patient and/or the parents, alone at home and
      return to the coordinator via the given envelope.

      During the study: Collect of the initial biopsies used for the hepatic angiosarcoma's
      diagnostic.

      End of the study: Telephone interview CRA/Patient and/or parents to complete the
      questionnaires (around one hour). From this data will be reconstitute the residential process
      of the patient and parents if it's about a child or an adolescent (collection of the
      successive addresses).

      Finally, water collections, according to a defined sampling protocol, at the tap of the
      different homes and places visited by the patients will be organized by the InvS in relation
      to the ARS within the scope of water quality controls, in order to evaluate the exposition to
      vinyl chloride monomer (VCM) by hydric ways.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of identifying incident cases of angiosarcoma liver from the network NetSarc</measure>
    <time_frame>At month 36</time_frame>
    <description>Feasibility of identifying incident cases of angiosarcoma of the liver (ASF) from the network NetSarc: number of sheets indicated and returned to the Promoter. 30 cases are expected, the cumulative number of incident cases will be measured over a period of 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prospective surveillance in France</measure>
    <time_frame>At month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of occupational risk factors and environmental</measure>
    <time_frame>At month 36</time_frame>
    <description>Data will be collected using a questionnaire with:
Exhaustive search of all occupational and environmental exposures as known or suspected risk factors for ASF
Reconstruction of residential history and haunts each case by means of a collection of successive addresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of biomarkers associated with human exposure Environmental old and new to vinyl chloride monomer</measure>
    <time_frame>At 36 month</time_frame>
    <description>Research suggestive of carcinogenesis related to CVM (identified in animal models and cohorts of workers exposed) biomarkers will be made by biological testing (blood and urine) adducts éthénobases kind resulting from the reaction of metabolites with CVM DNA and specific gene mutations k-ras and p53. Exposure to arsenic via the determination of Arsenic urinaire.sera sought.
The p53 and K-ras genes are also sequences from initial diagnostic biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the amount of vinyl chloride monomèredans successive addresses or nearby for cases without occupational exposure identified</measure>
    <time_frame>At month 36</time_frame>
    <description>Data will be collected using a questionnaire with:
- Assessment of the amount of vinyl chloride monomer (VCM) in successive addresses or nearby for cases without occupational exposure identified</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Patient with angiosarcoma of the liver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood and urine collections, questionnaire and telephone interview</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood and urine</intervention_name>
    <description>Blood collection and urine collection after consent of the patient</description>
    <arm_group_label>Patient with angiosarcoma of the liver</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>The patient complete the questionnaire alone at home</description>
    <arm_group_label>Patient with angiosarcoma of the liver</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone interview</intervention_name>
    <description>The patient will be contacted by the CRA for a telephone interview of around one hour</description>
    <arm_group_label>Patient with angiosarcoma of the liver</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with angiosarcoma of the liver (angiosarcoma immediately multifocal
             allowed) diagnosed by histology from the start of the study

          -  The patient's written Consent

        No exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LE MOAL Joelle, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Veille Sanitaire_Département Santé Environnement</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PENEL Nicolas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <zip>42 270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu / Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

